Form 4: Zymeworks Director Granted Stock Options and RSUs

Zymeworks Inc. Director Robert E. Landry received a grant of 11,500 stock options and 7,700 restricted stock units as part of his compensation.

Summary

• Robert E. Landry, a Director of Zymeworks Inc., was granted derivative securities on January 12, 2026.
• The grant included 11,500 stock options with an exercise price of $23.16.
• These stock options are scheduled to vest on January 12, 2027, and will expire on January 11, 2036.
• Additionally, 7,700 Restricted Stock Units (RSUs) were granted.
• Each RSU represents the contingent right to receive one share of common stock upon vesting.
• The RSUs are also scheduled to vest on January 12, 2027.

Sentiment

Score: 5

Explanation: Neutral, as this is a standard disclosure of director compensation through equity grants, reflecting routine corporate governance and incentive practices.

Positives

• The grant of stock options and restricted stock units aligns the director's financial interests with the long-term performance and shareholder value creation of Zymeworks Inc.
• Provides a direct incentive for the director to contribute to the company's future success and growth.

Negatives

• Potential for future dilution for existing shareholders upon the exercise of stock options and the vesting of restricted stock units.

Risks

• The ultimate value realized from the stock options is contingent on Zymeworks Inc.'s common stock price exceeding the exercise price of $23.16 at the time of exercise.
• The value of the restricted stock units upon vesting is dependent on the market price of Zymeworks Inc.'s common stock at that future date.

Future Outlook

NA

Industry Context

This filing details a routine equity compensation grant to a director, which is a common practice across various industries, including the biotechnology sector, to incentivize leadership and align their interests with the long-term performance of the company.

Stakeholder Impact

• Shareholders: Experience potential minor dilution upon the future exercise of options and vesting of RSUs, but benefit from enhanced alignment of director incentives with company performance.
• Director (Robert E. Landry): Receives equity-based compensation, directly linking his personal financial outcomes to the company's stock price performance.

Next Steps

• The granted stock options and restricted stock units are scheduled to vest on January 12, 2027.

Key Dates

Keywords

Zymeworks, ZYME, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Director Compensation, Equity Grant, Beneficial Ownership